Taiho Pharmaceutical Co., Ltd. clinical trials
A subsidiary of Otsuka Holdings Co., Ltd.
The registry lists 43 studies whose lead sponsor is Taiho Pharmaceutical Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 19, 2026.
Registry sponsor names on this page
- Taiho Pharmaceutical Co., Ltd.43 studies
Something wrong with this grouping? Tell us on the Otsuka Holdings Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 43 of 43. All Otsuka Holdings Co., Ltd. studies →
- Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene AbnormalitiesRecruitingNCT04683250Phase 1/2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic SyndromeRecruitingNCT04608110Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- AB122 Platform StudyRecruitingNCT04999761Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy(REACH-DMD)CompletedNCT04587908Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.CompletedNCT03175029Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase I Study of TAS-102 in Solid TumorsCompletedNCT02261532Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Exploratory Trial of TAS-303 in Female Patients With Stress Urinary IncontinenceCompletedNCT02906683Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Study of TAS3731 in Healthy AdultsCompletedNCT05691660Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous UrticariaCompletedNCT05335499Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male SubjectsCompletedNCT05621447Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Mass Balance Study of [14C] TAS-205 in Healthy VolunteersCompletedNCT04825431Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary IncontinenceCompletedNCT04512053Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric CancerCompletedNCT02322593Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Study of TAS-205 for Duchenne Muscular DystrophyCompletedNCT02246478Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in AsiaCompletedNCT01955837Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Efficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.CompletedNCT03605251Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Phase IIa Study of TAS-205 for Duchenne Muscular DystrophyCompletedNCT02752048Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular CarcinomaTerminatedNCT01465464Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical CancerCompletedNCT00770874Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid TumorsCompletedNCT01610479Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Study of TAS-303 in Female Patients With Stress Urinary IncontinenceCompletedNCT02562807Phase 1
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic CancerCompletedNCT00498225Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal CancerCompletedNCT00569335Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal CancerCompletedNCT00284258Phase 2/3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)CompletedNCT00569699Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal CancerCompletedNCT00569790Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Randomized Phase II Study of SOL for Untreated Metastatic Colorectal CancerCompletedNCT00721916Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Study of TAS-106 to Treat Head and Neck CancerTerminatedNCT00737360Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Study of TAS-109 to Treat Advanced Colorectal CancerTerminatedNCT00824161Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase I/II Study of TSU-68 for Advanced Hepatocellular CarcinomaCompletedNCT00784290Phase 1/2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Phase II Study of ABI-007 for Gastric CancerCompletedNCT00661167Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Study of S-1 Plus LV for Untreated Metastatic Colorectal CancerCompletedNCT00891332Phase 2
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Randomized Controlled Study of Postoperative Adjuvant Therapy of Uracil-tegafur (UFT) Compared With Cyclophosphamide/Methotrexate/5-fluorouracil (CMF) in Breast Cancer (NSAS-BC)CompletedNCT00152191Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic ChemotherapyCompletedNCT00359567Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-CC)CompletedNCT00152230Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -CompletedNCT00229424Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric CancerCompletedNCT00202969Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- A Randomized Controlled Study of Postoperative Adjuvant Chemotherapy of Uracil- Tegafur (UFT) Compared With Surgery Alone (NSAS-GC)CompletedNCT00152243Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)CompletedNCT00152217Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric CancerCompletedNCT00150670Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.
- The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)CompletedNCT00152178Phase 3
Sponsor listed in the registry: Taiho Pharmaceutical Co., Ltd.